title: Optical coherence tomography changes before the development of choroidal neovascularization in second eyes of patients with bilateral wet macular degeneration.
abstract: OBJECTIVE
  To describe the frequency of neovascular age-related macular degeneration (nAMD) in second eyes of patients undergoing ranibizumab therapy in their first eye and to evaluate the patterns of optical coherence tomography (OCT) abnormalities in fellow eyes before nAMD.
  
  
  METHODS
  Patients who developed choroidal neovascularization (CNV) in the second eye while on treatment for the first eye were identified. OCT scans of the second eyes, performed before the onset of CNV, were retrospectively examined and graded. Frequency of second eye involvement was estimated and patterns of progression of OCT abnormalities were described and classified.
  
  
  RESULTS
  In all, 65 out of 749 consecutive patients required ranibizumab in their second eye for treatment-naïve nAMD over a 2-year period. The mean interval from commencement of ranibizumab in first eye to conversion in second eye was 12 months (2-35.5 months). There were three patterns of CNV development: group A (12%, n=8) had no OCT abnormalities in the second eye just before developing CNV; group B (38%, n=25) had no abnormalities at baseline but developed OCT changes more than one visit before conversion and group C (50%, n=32) had OCT changes from baseline, which did not progress until just before conversion.
  
  
  CONCLUSIONS
  Patients with retinal pigment epithelial elevation without sub-retinal fluid on OCT in their fellow eyes have a high risk of progression to require therapy within a 2-year period. An anticipatory approach may be warranted, but a small group with completely normal OCT appearances can still develop lesions between visits.
authors.affiliation: Wolverhampton Eye Infirmary, New Cross Hospital, Wolverhampton, UK. kaarthur@doctors.net.uk
authors.forename: K N
authors.initials: KN
authors.lastname: Amissah-Arthur
authors.forename: S
authors.initials: S
authors.lastname: Panneerselvam
authors.forename: N
authors.initials: N
authors.lastname: Narendran
authors.forename: Y C
authors.initials: YC
authors.lastname: Yang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D020256:Choroidal Neovascularization / Q000453:epidemiology / Q000209:etiology / Q000473:pathology*; D018450:Disease Progression; D004739:England / Q000453:epidemiology; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology*; D008297:Male; D000069579:Ranibizumab; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab